Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18961788 | 0.90 | SMN1; SMN2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1992056 | 0.88 | TP53 (0.44) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1992054 | 0.88 | TP53 (0.44) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL2944175 | 0.88 | TP53 (0.44) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL16037703 | 0.85 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL29919339 | 0.83 | CHRNB2 (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL24906947 | 0.80 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL2824374 | 0.80 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL13738413 | 0.80 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL31196378 | 0.80 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023250375-A1 | CIRCULAR RNA ENCODING CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA | ORNA THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| EP-4289951-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| WO-2023056033-A1 | LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERING CIRCULAR POLYNUCLEOTIDES | ORNA THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| WO-2022261490-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2021226597-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021189059-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021113777-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2018081480-A1 | LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2018-05-03 | — | — | WO | disclosed |